Corium Receives a Buy from Jefferies

By Austin Angelo

Jefferies analyst David Steinberg reiterated a Buy rating on Corium (NASDAQ: CORI) today and set a price target of $8. The company’s shares opened today at $3.65.

According to, Steinberg is a 2-star analyst with an average return of 0.3% and a 47.7% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Supernus Pharmaceuticals, and Spectrum Pharmaceuticals.

Corium has an analyst consensus of Strong Buy, with a price target consensus of $10.

The company has a one year high of $8.33 and a one year low of $2.67. Currently, Corium has an average volume of 153.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Corium International, Inc. is a commercial stage biopharmaceutical company, which develops, manufactures and commercializes of specialty pharmaceutical products. The company development platforms enable transdermal delivery of large molecules or biologics, including vaccines, peptides and proteins, as well as small molecules that are otherwise difficult to deliver in a transdermal dosage form. Corium International was founded by Gary W. Cleary and Adrian L. Faasse, Jr. in 1995 and is headquartered in Menlo Park, CA.